Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interpace Biosciences's Other Operating Expense for the
three
months ended in Jun. 2026 was €0.00 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 was €0.00 Mil.
Interpace Biosciences's quarterly Other Operating Expense
increased
from Dec. 2025 (€0.00 Mil) to Mar. 2026 (€0.00 Mil) but then
declined
from Mar. 2026 (€0.00 Mil) to Jun. 2026 (€0.00 Mil).
Interpace Biosciences's annual Other Operating Expense
declined
from Dec. 2023 (€0.79 Mil) to Dec. 2024 (€-0.00 Mil) but then
increased
from Dec. 2024 (€-0.00 Mil) to Dec. 2025 (€-0.00 Mil).
Interpace Biosciences Other Operating Expense Related Terms
Interpace Biosciences Other Operating Expense Historical Data
* Premium members only.
The historical data trend for Interpace Biosciences's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interpace Biosciences Other Operating Expense Chart
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of €0.00 Mil mean?
Interpace Biosciences (STU:PF42) has a Other Operating Expense of €0.00 Mil as of Jun. 2026. Other operating expenses that a company records on its income statement. View historical data on Interpace Biosciences and its competitors.
Is Interpace Biosciences' Other Operating Expense too high?
Interpace Biosciences' current Other Operating Expense is €0.00 Mil. Overall, Interpace Biosciences has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Interpace Biosciences' Other Operating Expense compare to PRPO and ADVB?
Interpace Biosciences' Other Operating Expense of €0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Medical Diagnostics & Research company?
A good Other Operating Expense depends on the Medical Diagnostics & Research industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Interpace Biosciences and its competitors. Interpace Biosciences's current Other Operating Expense is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Interpace Biosciences stock overvalued right now?
Interpace Biosciences (STU:PF42) has a current Other Operating Expense of €0.00 Mil. The stock's GF Value™ is €0.17, compared to a current price of €1.34 — trading 688.2% above its estimated fair value. The current Other Operating Expense is €0.00 Mil. Interpace Biosciences' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Interpace Biosciences (STU:PF42), the current Other Operating Expense is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Interpace Biosciences (STU:PF42) Overvalued in 2026?
Based on GuruFocus' analysis, Interpace Biosciences stock appears to be overvalued.
The current stock price of €1.34 is trading 688.2% above its estimated GF Value™ of €0.17.
Key valuation signals for STU:PF42:
Other Operating Expense: €0.00 Mil
GF Value™: €0.17 vs. price of €1.34 (688.2% above fair value)
No single metric tells the full story. See the STU:PF42 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Interpace Biosciences Inc provides esoteric molecular diagnostic testing and pathology services to aid physicians in evaluating cancer risk in patients with indeterminate biopsies and a perceived high risk of cancer based on clinical features. The company develops and commercializes genomic tests and related first-line assays that can personalize medicine and help improve patient diagnosis and management. Its clinical customers mainly consist of physicians, hospitals, cancer centers, commercial laboratories, pathology groups, and clinics. The various diagnostic tests offered by the company include ThyGeNEXT and ThyraMIRv2 for the detection of thyroid cancer.
41GF Score
Get the complete analysis for STU:PF42
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:PF42 has been successfully added to your 
